Staff turnover in EUR-40,543177,5652,511,811541,201897,481
Staff turnover in EUR-40,543177,5652,511,811541,201897,481
The share: stated in EUR20212022202320242025
Shares outstanding (in mn.)54.610.751.2614.531.40
Dividend per share-----
Basic earnings per share-16.20-11.705.18-3.69-3.78
P/L in EUR million under IAS/IFRS20212022202320242025
Turnover-1.67.5103.439.177.2
Operating income (EBIT)-41.9-55.182.7-38.1-41.4
Earnings before taxes-54.7-70.654.8-41.7-49.1
Annual net profit/ loss-55.5-71.154.8-42.0-49.2
Balance sheet in EUR million under IAS/IFRS20212022202320242025
Assets
Total current assets24.63.134.775.880.2
Total fixed assets66.560.775.076.767.8
Total assets91.163.7109.6152.5148.1
Liabilities
Total short-term liabilities32.849.444.346.162.2
Total long-term liabilities57.058.05.478.697.7
Total provisions4.826.83.97.76.5
Equity capital1.3-43.759.927.7-11.8
Total liabilities91.163.7109.6152.5148.1
Management:
Dario Eklund
Oliver Kronenberg
Catherine Isted
Geert Jan van Daal
Marc Schrader
Shabir Hasham
Board:
Melanie Rolli
Srishti Gupta
Bradley Meyer
Philipp Gutzwiller
Thomas Meier
Shareholding in %:
Catalyst Pharmaceuticals, Inc. 9.53
Dario Eklund 0.74
Entrepreneur Partners AG 0.74
IFS Independent Financial Services AG 0.74
Idorsia Ltd. 2.72
Joh. Berenberg, Gossler & Co. KG (Investment Management) 1.50
Nxera Pharma Co., Ltd. 2.99
Santhera Pharmaceuticals Holding AG 4.30
UBS Asset Management Switzerland AG 2.29
Zürcher Kantonalbank (Investment Management) 1.89
Freefloat 72.56
Address: Hohenrainstrasse 24, 4133 Pratteln
T: +41-61-906-89-50
F: +41-61-906-89-51
I: http://www.santhera.com
E: [email protected]